IFNG | OmnibusX

Name	Number of supported studies	Average coverage
natural killer cell	22 studies	31% ± 14%	Explore
CD8-positive, alpha-beta T cell	18 studies	26% ± 13%	Explore
mature NK T cell	10 studies	24% ± 8%	Explore
effector CD8-positive, alpha-beta T cell	6 studies	31% ± 10%	Explore
CD16-negative, CD56-bright natural killer cell, human	6 studies	31% ± 10%	Explore
T cell	5 studies	29% ± 12%	Explore
CD16-positive, CD56-dim natural killer cell, human	5 studies	35% ± 10%	Explore
CD8-positive, alpha-beta memory T cell	5 studies	27% ± 7%	Explore
gamma-delta T cell	5 studies	21% ± 3%	Explore
exhausted T cell	4 studies	29% ± 7%	Explore
CD4-positive, alpha-beta cytotoxic T cell	3 studies	19% ± 3%	Explore
effector memory CD8-positive, alpha-beta T cell	3 studies	25% ± 4%	Explore

II. Expression across tissues

sc-RNAseq data

Insufficient scRNA-seq data for expression of IFNG at tissue level.

Tissue	GTEx Coverage	GTEx Average TPM	GTEx Number of samples	TCGA Coverage	TCGA Average TPM	TCGA Number of samples
lung	78%	96.31	451 / 578	50%	2.14	577 / 1155
lymph node	0%	0	0 / 0	100%	30.91	29 / 29
spleen	98%	74.63	237 / 241	0%	0	0 / 0
tonsil	0%	0	0 / 0	84%	5.34	38 / 45
liver	62%	44.67	141 / 226	13%	0.47	53 / 406
uterus	26%	5.54	44 / 170	48%	2.77	220 / 459
kidney	43%	12.75	38 / 89	29%	1.38	257 / 901
peripheral blood	70%	276.20	646 / 929	0%	0	0 / 0
thymus	43%	21.05	279 / 653	21%	0.70	129 / 605
bladder	29%	5.05	6 / 21	32%	1.44	163 / 504
stomach	23%	11.32	83 / 359	37%	1.75	105 / 286
skin	11%	1.62	198 / 1809	48%	3.43	227 / 472
breast	33%	6.55	151 / 459	26%	1.11	292 / 1118
intestine	28%	7.33	269 / 966	30%	1.01	160 / 527
adipose	45%	20.23	537 / 1204	0%	0	0 / 0
esophagus	13%	1.96	182 / 1445	31%	0.96	57 / 183
prostate	20%	2.58	50 / 245	9%	0.19	45 / 502
ovary	13%	1.90	23 / 180	15%	0.35	65 / 430
heart	27%	6.41	230 / 861	0%	0	0 / 0
blood vessel	26%	6.89	342 / 1335	0%	0	0 / 0
adrenal gland	13%	2.18	33 / 258	2%	0.04	5 / 230
brain	13%	1.99	338 / 2642	1%	0.18	7 / 705
pancreas	3%	0.40	11 / 328	10%	0.40	18 / 178
eye	0%	0	0 / 0	10%	0.41	8 / 80
muscle	3%	0.32	27 / 803	0%	0	0 / 0
abdomen	0%	0	0 / 0	0%	0	0 / 0
bone marrow	0%	0	0 / 0	0%	0	0 / 0
diaphragm	0%	0	0 / 0	0%	0	0 / 0
gingiva	0%	0	0 / 0	0%	0	0 / 0
nasal cavity	0%	0	0 / 0	0%	0	0 / 0
nasopharynx	0%	0	0 / 0	0%	0	0 / 0
nose	0%	0	0 / 0	0%	0	0 / 0
placenta	0%	0	0 / 0	0%	0	0 / 0
spinal column	0%	0	0 / 0	0%	0	0 / 0
ureter	0%	0	0 / 0	0%	0	0 / 1

III. Associated gene sets

GO_0051712	Biological process	positive regulation of killing of cells of another organism
GO_0042531	Biological process	positive regulation of tyrosine phosphorylation of STAT protein
GO_0097191	Biological process	extrinsic apoptotic signaling pathway
GO_0090312	Biological process	positive regulation of protein deacetylation
GO_0032722	Biological process	positive regulation of chemokine production
GO_0050796	Biological process	regulation of insulin secretion
GO_0033141	Biological process	positive regulation of peptidyl-serine phosphorylation of STAT protein
GO_0050766	Biological process	positive regulation of phagocytosis
GO_1904798	Biological process	positive regulation of core promoter binding
GO_0032755	Biological process	positive regulation of interleukin-6 production
GO_0045348	Biological process	positive regulation of MHC class II biosynthetic process
GO_0001774	Biological process	microglial cell activation
GO_0051044	Biological process	positive regulation of membrane protein ectodomain proteolysis
GO_0051770	Biological process	positive regulation of nitric-oxide synthase biosynthetic process
GO_1904783	Biological process	positive regulation of NMDA glutamate receptor activity
GO_0010629	Biological process	negative regulation of gene expression
GO_0030225	Biological process	macrophage differentiation
GO_0048143	Biological process	astrocyte activation
GO_2000273	Biological process	positive regulation of signaling receptor activity
GO_0032747	Biological process	positive regulation of interleukin-23 production
GO_0032834	Biological process	positive regulation of CD4-positive, CD25-positive, alpha-beta regulatory T cell differentiation involved in immune response
GO_2000309	Biological process	positive regulation of tumor necrosis factor (ligand) superfamily member 11 production
GO_0009615	Biological process	response to virus
GO_0051607	Biological process	defense response to virus
GO_0010628	Biological process	positive regulation of gene expression
GO_0032735	Biological process	positive regulation of interleukin-12 production
GO_0042307	Biological process	positive regulation of protein import into nucleus
GO_0050769	Biological process	positive regulation of neurogenesis
GO_0060333	Biological process	type II interferon-mediated signaling pathway
GO_0000122	Biological process	negative regulation of transcription by RNA polymerase II
GO_1903543	Biological process	positive regulation of exosomal secretion
GO_1900222	Biological process	negative regulation of amyloid-beta clearance
GO_0019222	Biological process	regulation of metabolic process
GO_0060550	Biological process	positive regulation of fructose 1,6-bisphosphate 1-phosphatase activity
GO_0034393	Biological process	positive regulation of smooth muscle cell apoptotic process
GO_0006959	Biological process	humoral immune response
GO_0031334	Biological process	positive regulation of protein-containing complex assembly
GO_1901857	Biological process	positive regulation of cellular respiration
GO_0045672	Biological process	positive regulation of osteoclast differentiation
GO_0032731	Biological process	positive regulation of interleukin-1 beta production
GO_0002250	Biological process	adaptive immune response
GO_0098586	Biological process	cellular response to virus
GO_0030857	Biological process	negative regulation of epithelial cell differentiation
GO_1903078	Biological process	positive regulation of protein localization to plasma membrane
GO_0060559	Biological process	positive regulation of calcidiol 1-monooxygenase activity
GO_1904440	Biological process	positive regulation of iron ion import across plasma membrane
GO_1902004	Biological process	positive regulation of amyloid-beta formation
GO_0038196	Biological process	type III interferon-mediated signaling pathway
GO_0010508	Biological process	positive regulation of autophagy
GO_0048662	Biological process	negative regulation of smooth muscle cell proliferation
GO_0045429	Biological process	positive regulation of nitric oxide biosynthetic process
GO_1902948	Biological process	negative regulation of tau-protein kinase activity
GO_0002281	Biological process	macrophage activation involved in immune response
GO_0006915	Biological process	apoptotic process
GO_0008284	Biological process	positive regulation of cell population proliferation
GO_0050729	Biological process	positive regulation of inflammatory response
GO_0001819	Biological process	positive regulation of cytokine production
GO_0032700	Biological process	negative regulation of interleukin-17 production
GO_0060552	Biological process	positive regulation of fructose 1,6-bisphosphate metabolic process
GO_0060557	Biological process	positive regulation of vitamin D biosynthetic process
GO_0071902	Biological process	positive regulation of protein serine/threonine kinase activity
GO_0045821	Biological process	positive regulation of glycolytic process
GO_0045892	Biological process	negative regulation of DNA-templated transcription
GO_0007259	Biological process	cell surface receptor signaling pathway via JAK-STAT
GO_0010634	Biological process	positive regulation of epithelial cell migration
GO_0032760	Biological process	positive regulation of tumor necrosis factor production
GO_0150076	Biological process	neuroinflammatory response
GO_0007166	Biological process	cell surface receptor signaling pathway
GO_0005615	Cellular component	extracellular space
GO_0005576	Cellular component	extracellular region
GO_0005133	Molecular function	type II interferon receptor binding
GO_0005515	Molecular function	protein binding
GO_0005125	Molecular function	cytokine activity

IV. Literature review

[source]

Gene name	IFNG
Protein name	Interferon gamma (IFN-gamma) Interferon gamma (IFN-gamma) (Immune interferon)
Synonyms
Description	FUNCTION: Type II interferon produced by immune cells such as T-cells and NK cells that plays crucial roles in antimicrobial, antiviral, and antitumor responses by activating effector immune cells and enhancing antigen presentation . Primarily signals through the JAK-STAT pathway after interaction with its receptor IFNGR1 to affect gene regulation . Upon IFNG binding, IFNGR1 intracellular domain opens out to allow association of downstream signaling components JAK2, JAK1 and STAT1, leading to STAT1 activation, nuclear translocation and transcription of IFNG-regulated genes. Many of the induced genes are transcription factors such as IRF1 that are able to further drive regulation of a next wave of transcription . Plays a role in class I antigen presentation pathway by inducing a replacement of catalytic proteasome subunits with immunoproteasome subunits . In turn, increases the quantity, quality, and repertoire of peptides for class I MHC loading . Increases the efficiency of peptide generation also by inducing the expression of activator PA28 that associates with the proteasome and alters its proteolytic cleavage preference . Up-regulates as well MHC II complexes on the cell surface by promoting expression of several key molecules such as cathepsins B/CTSB, H/CTSH, and L/CTSL . Participates in the regulation of hematopoietic stem cells during development and under homeostatic conditions by affecting their development, quiescence, and differentiation (By similarity). . FUNCTION: Type II interferon produced by immune cells such as T-cells and NK cells that plays crucial roles in antimicrobial, antiviral, and antitumor responses by activating effector immune cells and enhancing antigen presentation. Primarily signals through the JAK-STAT pathway after interaction with its receptor IFNGR1 to affect gene regulation. Upon IFNG binding, IFNGR1 intracellular domain opens out to allow association of downstream signaling components JAK2, JAK1 and STAT1, leading to STAT1 activation, nuclear translocation and transcription of IFNG-regulated genes. Many of the induced genes are transcription factors such as IRF1 that are able to further drive regulation of a next wave of transcription. Plays a role in class I antigen presentation pathway by inducing a replacement of catalytic proteasome subunits with immunoproteasome subunits. In turn, increases the quantity, quality, and repertoire of peptides for class I MHC loading. Increases the efficiency of peptide generation also by inducing the expression of activator PA28 that associates with the proteasome and alters its proteolytic cleavage preference. Up-regulates as well MHC II complexes on the cell surface by promoting expression of several key molecules such as cathepsins B/CTSB, H/CTSH, and L/CTSL. Participates in the regulation of hematopoietic stem cells during development and under homeostatic conditions by affecting their development, quiescence, and differentiation. .
Accessions	P01579 A8YQE4 ENST00000229135.4

IFNG report

I. Expression across cell types

II. Expression across tissues

III. Associated gene sets

IV. Literature review